

#	Biosimilar	Applicant	Reference Product	aBLA Approval	U.S. Launch	Related BPCIA Litigation
1	ZARXIO (filgrastim-sndz)	Sandoz	NEUPOGEN [#1]	<a href="#">Mar. 6, 2015</a>	<a href="#">Sept. 3, 2015</a>	<a href="#">Amgen v. Sandoz</a>
2	INFLECTRA (infliximab-dyyb)	Celltrion	REMICADE [#1]	<a href="#">Apr. 5, 2016</a>	<a href="#">Nov. 21, 2016</a>	<a href="#">Janssen v. Celltrion</a>
3	ERELZI (etanercept-szszs)	Sandoz	ENBREL [#1]	<a href="#">Aug. 30, 2016</a>		<a href="#">Immunex v. Sandoz</a>
4	AMJEVITA (adalimumab-atto)	Amgen	HUMIRA [#1]	<a href="#">Sept. 23, 2016</a>	<a href="#">January 31, 2023</a>	<a href="#">AbbVie v. Amgen</a>
5	RENFLEXIS (infliximab-abda)	Samsung Bioepis	REMICADE [#2]	<a href="#">Apr. 21, 2017</a>	<a href="#">July 24, 2017</a>	<a href="#">Janssen v. Samsung Bioepis</a>
6	CYLTEZO (adalimumab-adbm)	Boehringer Ingelheim	HUMIRA [#2]	<a href="#">Aug. 25, 2017</a>		<a href="#">AbbVie v. BI</a>
7	MVASI (bevacizumab-awwb)	Amgen	AVASTIN [#1]	<a href="#">Sept. 14, 2017</a>	<a href="#">July 19, 2019</a>	<a href="#">Genentech v. Amgen</a>
8	OGIVRI (trastuzumab-dkst)	Mylan	HERCEPTIN [#1]	<a href="#">Dec. 1, 2017</a>	<a href="#">Dec. 2, 2019</a>	None
9	IXIFI (infliximab-qbtx)	Pfizer	REMICADE [#3]	<a href="#">Dec. 13, 2017</a>		None
10	RETACRIT (epoetin alfa-epbx)	Hospira	EPOGEN/ PROCRIT [#1]	<a href="#">May 15, 2018</a>	<a href="#">Nov. 12, 2018</a>	<a href="#">Amgen v. Hospira</a>
11	FULPHILA (pegfilgrastim-jmdb)	Mylan	NEULASTA [#1]	<a href="#">June 4, 2018</a>	<a href="#">July 26, 2018</a>	<a href="#">Amgen v. Mylan</a>
12	NIVESTYM (filgrastim-aafi)	Pfizer	NEUPOGEN [#2]	<a href="#">July 20, 2018</a>	<a href="#">Oct. 1, 2018</a>	<a href="#">Amgen v. Hospira</a>
13	HYRIMOZ (adalimumab-adaz)	Sandoz	HUMIRA [#3]	<a href="#">Oct. 30, 2018 (approval of 50 mg/ml product)</a>  <a href="#">March 21, 2023 (approval of 100 mg/ml product)</a>		<a href="#">AbbVie v. Sandoz</a>
14	UDENYCA (pegfilgrastim-cbqv)	Coherus	NEULASTA [#2]	<a href="#">Nov. 2, 2018</a>	<a href="#">Jan. 3, 2019</a>	<a href="#">Amgen v. Coherus</a>
15	TRUXIMA (rituximab-abbs)	Celltrion	RITUXAN [#1]	<a href="#">Nov. 28, 2018</a>	<a href="#">Nov. 11, 2019</a>	<a href="#">Genentech v. Celltrion</a>
16	HERZUMA (trastuzumab-pkrb)	Celltrion	HERCEPTIN [#2]	<a href="#">Dec. 14, 2018</a>	<a href="#">Mar. 16, 2020</a>	<a href="#">Genentech v. Celltrion</a>

17	ONTRUZANT (trastuzumab-dttb)	Samsung Bioepis	HERCEPTIN [#3]	<a href="#">Jan. 18, 2019</a>	<a href="#">Apr. 15, 2020</a>	<a href="#">Genentech v. Samsung Bioepis</a>
18	TRAZIMERA (trastuzumab-qyyp)	Pfizer	HERCEPTIN [#4]	<a href="#">Mar. 11, 2019</a>	<a href="#">Feb. 15, 2020</a>	<a href="#">Genentech v. Pfizer</a>
19	ETICOVO (etanercept-ykro)	Samsung Bioepis	ENBREL [#2]	<a href="#">Apr. 25, 2019</a>		<a href="#">Immunex v. Samsung Bioepis</a>
20	KANJINTI (trastuzumab-anns)	Amgen	HERCEPTIN [#5]	<a href="#">June 13, 2019</a>	<a href="#">July 19, 2019</a>	<a href="#">Genentech v. Amgen</a>
21	ZIRABEV (bevacizumab-bvzr)	Pfizer	AVASTIN [#2]	<a href="#">June 28, 2019</a>	<a href="#">Dec. 31, 2019</a>	<a href="#">Genentech v. Pfizer</a>
22	RUXIENCE (rituximab-pvvr)	Pfizer	RITUXAN [#2]	<a href="#">July 23, 2019</a>	<a href="#">Jan. 23, 2020</a>	None
23	HADLIMA (adalimumab-bwwd)	Samsung Bioepis	HUMIRA [#4]	<a href="#">July 23, 2019</a> (50 mg/ml)  August 15, 2022 (100 mg/ml)		None
24	ZIEXTENZO (pegfilgrastim-bmez)	Sandoz	NEULASTA [#3]	<a href="#">Nov. 4, 2019</a>	<a href="#">Nov. 15, 2019</a>	<a href="#">Amgen v. Sandoz</a>
25	ABRILADA (adalimumab-afzb)	Pfizer	HUMIRA [#5]	<a href="#">Nov. 15, 2019</a>		None
26	AVSOLA (infliximab-axxq)	Amgen	REMICADE [#4]	<a href="#">Dec. 6, 2019</a>	July 2020	None
27	NYVEPRIA (pegfilgrastim-apgf)	Pfizer	NEULASTA [#4]	<a href="#">June 10, 2020</a>	Late 2020 or early 2021	<a href="#">Amgen v. Hospira</a>
28	HULIO (adalimumab-fkjp)	Mylan	HUMIRA [#6]	<a href="#">July 6, 2020</a>		None
29	RIABNI (rituximab-arrx)	Amgen	RITUXAN [#3]	Dec. 17, 2020	Jan. 12, 2021	None
30	SEMGLEE (insulin glargine-yfng)	Viartis	LANTUS [#1]	<a href="#">July 28, 2021</a>	Nov. 16, 2021	None
31	BYOOVIZ (ranibizumab-nuna)	Biogen/Samsung Bioepis	LUCENTIS [#1]	<a href="#">Sep. 20, 2021</a>	June 2, 2022	None
32	YUSIMRY (adalimumab-aqvh)	Coherus	HUMIRA [#7]	<a href="#">Dec. 20, 2021</a>		None
33	REZVOGLAR (insulin glargine-aglr)	Eli Lilly	LANTUS [#2]	<a href="#">Dec. 20, 2021</a> (original approval)	April 1, 2023	None

				<a href="#">Nov. 16, 2022</a> (approved as an interchangeable)		
34	RELEUKO (filgrastim-ayow)	Amneal/Kashiv	NEUPOGEN [#3]	<a href="#">Mar. 1, 2022</a>	<a href="#">Nov. 22, 2022</a>	None
35	ALYMSYS (bevacizumab-maly)	Amneal/mAbxience	AVASTIN [#3]	<a href="#">April 13, 2022</a>	<a href="#">Oct. 3, 2022</a>	None
36	FYLNETRA (pegfilgrastim-pbbk)	Amneal/Kashiv	NEULASTA [#5]	<a href="#">May 27, 2022</a>	<a href="#">May 16, 2023</a>	None
37	CIMERLI (ranibizumab-eqrn)	Coherus	LUCENTIS [#2]	<a href="#">August 2, 2022</a>	<a href="#">Oct. 3, 2022</a>	None
38	STIMUFEND (pegfilgrastim-fpgk)	Fresenius Kabi	NEULASTA [#6]	<a href="#">Sept. 1, 2022</a>	<a href="#">Feb. 16, 2023</a>	None
39	VEGZELMA (bevacizumab-adcd)	Celltrion	AVASTIN (#4)	<a href="#">Sept. 27, 2022</a>	<a href="#">April 17, 2023</a>	None
40	IDACIO (adalimumab-aacf)	Fresenius Kabi	HUMIRA [#8]	December 14, 2022		None